Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation.
about
Comparison of gefitinib as first- and second-line therapy for advanced lung adenocarcinoma patients with positive exon 21 or 19 del epidermal growth factor receptor mutation.
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Comparison of gefitinib as fir ...... owth factor receptor mutation.
@ast
Comparison of gefitinib as fir ...... owth factor receptor mutation.
@en
type
label
Comparison of gefitinib as fir ...... owth factor receptor mutation.
@ast
Comparison of gefitinib as fir ...... owth factor receptor mutation.
@en
prefLabel
Comparison of gefitinib as fir ...... owth factor receptor mutation.
@ast
Comparison of gefitinib as fir ...... owth factor receptor mutation.
@en
P2093
P2860
P356
P1476
Comparison of gefitinib as fir ...... owth factor receptor mutation.
@en
P2093
Haijun Zhang
Nishant Patel
Pingping Wu
P2860
P304
P356
10.2147/CMAR.S138643
P407
P577
2017-06-28T00:00:00Z